adalimumab

Study reports comparable treatment effects of biosimilars and reference biologics in rheumatoid arthritis

by

Adalimumab, infliximab, and etanercept biosimilars were found to have clinically equal treatment effects compared to their reference biologics for the treatment of rheumatoid arthritis (RA), according to a review and meta-analysis published in JAMA Network Open. The study included a total of 10,642 RA patients who were using biosimilars of the drugs adalimumab, etanercept, and … Read more

Olokizumab, a new drug for managing rheumatoid arthritis

by

Despite the recent therapeutic advances, nearly 25% of patients are refractory to the treatment regimens. The findings of an international multi-centre study led by MedUni Vienna, published in the New England Journal of Medicine, have reported olokizumab as a newer treatment option with promising results for the management of RA. Olokizumab, the humanized monoclonal antibody, … Read more